Kronos Bio Past Earnings Performance
Past criteria checks 0/6
Kronos Bio's earnings have been declining at an average annual rate of -15%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 90.2% per year.
Key information
-15.0%
Earnings growth rate
25.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 90.2% |
| Return on equity | -77.0% |
| Net Margin | -867.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being
Jun 20
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Jun 11Kronos Bio: Still Promising But Riskier Following ASCO Update
Jun 05Kronos Bio: Underestimated Drug Discovery Platform
May 06Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jan 19We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate
Aug 21We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully
Feb 22Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?
Nov 01Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib
Aug 16Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?
Jul 07We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely
Feb 01How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?
Mar 03Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares
Jan 09
Kronos Bio EPS misses by $4.10
Nov 18Revenue & Expenses Breakdown
How Kronos Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10 | -86 | 32 | 56 |
| 30 Jun 24 | 8 | -103 | 36 | 69 |
| 31 Mar 24 | 8 | -116 | 40 | 76 |
| 31 Dec 23 | 6 | -113 | 42 | 81 |
| 30 Sep 23 | 4 | -119 | 43 | 86 |
| 30 Jun 23 | 3 | -120 | 44 | 84 |
| 31 Mar 23 | 1 | -123 | 45 | 86 |
| 31 Dec 22 | 0 | -133 | 46 | 91 |
| 30 Sep 22 | 0 | -164 | 48 | 118 |
| 30 Jun 22 | 0 | -165 | 46 | 120 |
| 31 Mar 22 | 0 | -161 | 45 | 117 |
| 31 Dec 21 | 0 | -151 | 42 | 110 |
| 30 Sep 21 | 0 | -122 | 39 | 71 |
| 30 Jun 21 | 0 | -128 | 35 | 63 |
| 31 Mar 21 | 0 | -108 | 27 | 50 |
| 31 Dec 20 | 0 | -88 | 19 | 39 |
| 30 Sep 20 | 0 | -61 | 11 | 32 |
| 30 Jun 20 | 0 | -25 | 6 | 20 |
| 31 Mar 20 | 0 | -20 | 4 | 17 |
| 31 Dec 19 | 0 | -16 | 3 | 13 |
Quality Earnings: KRON is currently unprofitable.
Growing Profit Margin: KRON is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KRON is unprofitable, and losses have increased over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare KRON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KRON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: KRON has a negative Return on Equity (-77.02%), as it is currently unprofitable.